Real-world Evidence Comparing Oral Anticoagulants in non-valvular Atrial Fibrillation: A Systematic Review and Network meta-analysis

References

• Writing Group Members ; Lloyd-JonesD, Adams RJ, Brown TMet al.Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation, 121(7), e46–e215 (2010).
   PubMed Web of Science ®Google Scholar
• January CT , WannLS, CalkinsHet al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation, 140(2), e125–e151 (2019).
   PubMed Web of Science ®Google Scholar
• Lowenstern A , Al-KhatibSM, SharanLet al. Interventions for preventing thromboembolic events in patients with atrial fibrillation: a systematic review. Ann. Intern. Med., 169(11), 774–787 (2018).
   PubMed Web of Science ®Google Scholar
• January CT , WannLS, CalkinsHet al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol., 74(1), 104–132 (2019).
   PubMed Web of Science ®Google Scholar
• Connolly SJ , EzekowitzMD, YusufSet al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 361(12), 1139–1151 (2009).
   PubMed Web of Science ®Google Scholar
• Patel MR , MahaffeyKW, GargJet al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med., 365(10), 883–891 (2011).
   PubMed Web of Science ®Google Scholar
• Granger CB , AlexanderJH, McmurrayJJet al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 365(11), 981–992 (2011).
   PubMed Web of Science ®Google Scholar
• Giugliano RP , RuffCT, BraunwaldEet al. Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 369(22), 2093–2104 (2013).
   PubMed Web of Science ®Google Scholar
• Hindricks G , PotparaT, DagresNet al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur. Heart J., 42(5), 373–498 (2021).
   PubMed Web of Science ®Google Scholar
• Bai Y , DengH, ShantsilaA, LipGY. Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis. Stroke, 48(4), 970–976 (2017).
   PubMed Web of Science ®Google Scholar
• Bai Y , GuoSD, DengHet al. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis. Age. Ageing, 47(1), 9–17 (2018).
   PubMed Web of Science ®Google Scholar
• Bai Y , ShiXB, MaCS, LipGYH. Meta-analysis of effectiveness and safety of oral anticoagulants in atrial fibrillation with focus on apixaban. Am. J. Cardiol., 120(9), 1689–1695 (2017).
   PubMed Web of Science ®Google Scholar
• Bundhun PK , SoogundMZ, TeeluckAR, PursunM, BhurtuA, HuangWQ. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis. BMC Cardiovasc. Disord., 17(1), 15 (2017).
   PubMedGoogle Scholar
• Carmo J , MoscosoCosta F, FerreiraJ, MendesM. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. Thromb. Haemost., 116(4), 754–763 (2016).
   PubMed Web of Science ®Google Scholar
• Darwiche W , Bejan-AngoulvantT, AngoulvantD, BabutyD, FauchierL. Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonists. Meta-analysis of observational analyses. Thromb. Haemost., 116(6), 1150–1158 (2016).
   PubMed Web of Science ®Google Scholar
• Deitelzweig S , FarmerC, LuoXet al. Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis. Curr. Med. Res. Opin., 34(3), 487–498 (2018).
   PubMed Web of Science ®Google Scholar
• Deitelzweig S , FarmerC, LuoXet al. Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies. Curr. Med. Res. Opin., 33(9), 1583–1594 (2017).
   PubMed Web of Science ®Google Scholar
• Escobar C , Marti-AlmorJ, PerezCabeza A, Martinez-ZapataMJ. Direct oral anticoagulants versus vitamin K antagonists in real-life patients with atrial fibrillation. A systematic review and meta-analysis. Rev. Esp. Cardiol. (Engl. Ed.), 72(4), 305–316 (2019).
   PubMed Web of Science ®Google Scholar
• Li G , HolbrookA, JinYet al. Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials. Eur. J. Epidemiol., 31(6), 541–561 (2016).
   PubMed Web of Science ®Google Scholar
• Ntaios G , PapavasileiouV, MakaritsisK, VemmosK, MichelP, LipGYH. Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-k antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke, 48(9), 2494–2503 (2017).
   PubMed Web of Science ®Google Scholar
• Proietti M , RomanazziI, RomitiGF, FarcomeniA, LipGYH. Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke, 49(1), 98–106 (2018).
   PubMed Web of Science ®Google Scholar
• Romanelli RJ , NoltingL, DolginskyM, KymE, OrricoKB. Dabigatran versus warfarin for atrial fibrillation in real-world clinical practice: a systematic review and meta-analysis. Circ. Cardiovasc. Qual. Outcomes, 9(2), 126–134 (2016).
   PubMed Web of Science ®Google Scholar
• Vinceti M , FilippiniT, MalagoliCet al. Amyotrophic lateral sclerosis incidence following exposure to inorganic selenium in drinking water: a long-term follow-up. Environ. Res., 179, 108742 (2019).
   PubMed Web of Science ®Google Scholar
• Hutton B , SalantiG, CaldwellDMet al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann. Intern. Med., 162(11), 777–784 (2015).
   PubMed Web of Science ®Google Scholar
• Liberati A , AltmanDG, TetzlaffJet al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. BMJ339, b2700 (2009).
   Google Scholar
• Higgins JPT , ThomasJ, ChandlerJet al.et al. ( Eds). Cochrane Handbook for Systematic Reviews of Interventions. Version 6.1 (updated September 2020). Cochrane (2020). www.training.cochrane.org/handbook
   Google Scholar
• Sterne JA , HernanMA, ReevesBCet al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 355, i4919 (2016).
   PubMed Web of Science ®Google Scholar
• Senn SJ . Overstating the evidence: double counting in meta-analysis and related problems. BMC Med. Res. Methodol., 9, 10 (2009).
   PubMed Web of Science ®Google Scholar
• Dias S , WeltonNJ, SuttonAJ, AdesA. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled TrialsNational Institute for Health and Care Excellence (NICE), London, UK (2011).
   Google Scholar
• Turner RM , JacksonD, WeiY, ThompsonSG, HigginsJP. Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis. Stat. Med., 34(6), 984–998 (2015).
   PubMed Web of Science ®Google Scholar
• Higgins JP , ThompsonSG, DeeksJJ, AltmanDG. Measuring inconsistency in meta-analyses. BMJ, 327(7414), 557–560 (2003).
   PubMed Web of Science ®Google Scholar
• Lunn D , SpiegelhalterD, ThomasA, BestN. The BUGS project: evolution, critique and future directions. Stat. Med., 28(25), 3049–3067 (2009).
   PubMed Web of Science ®Google Scholar
• He Y , WongIC, LiXet al. The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies. Br. J. Clin. Pharmacol., 82(1), 285–300 (2016).
   PubMed Web of Science ®Google Scholar
• Lip GY , LarsenTB, SkjothF, RasmussenLH. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J. Am. Coll. Cardiol., 60(8), 738–746 (2012).
   PubMed Web of Science ®Google Scholar
• Mantha S , AnsellJ. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb. Haemost., 108(3), 476–484 (2012).
   PubMed Web of Science ®Google Scholar
• Rasmussen LH , LarsenTB, GraungaardT, SkjøthF, LipGY. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ, 345, e7097 (2012).
   PubMed Web of Science ®Google Scholar
• Sterne JA , BodaliaPN, BrydenPAet al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol. Assess., 21(9), 1–386 (2017).
   Web of Science ®Google Scholar